Sign In
Buy AMLX
$13.20
-0.0900 (-0.677%)
At Close: Jun 03, 2026
2 Supercharged Growth Stocks to Buy Right Now
04:00pm, Sunday, 14'th May 2023
Growth stocks have been top-performers during the first five months of 2023. This broad-based rally is in danger of stalling because of numerous storm clouds on the horizon.
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2023 Earnings Call Transcript
01:03pm, Sunday, 14'th May 2023
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co
Final Trades: IBM, Exxon Mobil, Amylyx, and Home Depot
06:03pm, Friday, 12'th May 2023
The final trades of the day with the Fast Money traders.
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 Earnings and Revenues Surpass Estimates
07:02pm, Thursday, 11'th May 2023
Amylyx Pharmaceuticals, Inc. (AMLX) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to loss of $0.93 per share a y
3 Biotechs That Might Get Bought Out in 2023
11:30am, Wednesday, 26'th Apr 2023
With multiple blockbuster drugs going off patent this decade, pharma companies are expected to ratchet up their M&A activities. These three companies sport high-value assets that could attract suitors
Amylyx (AMLX) Doses First Patient in Wolfram Syndrome Study
03:12pm, Friday, 14'th Apr 2023
Amylyx (AMLX) progresses with the phase II study of pipeline candidate AMX0035 for the treatment of Wolfram syndrome as it doses the first patient.
7 Biotech Stocks to Buy for 100% Returns
01:19pm, Sunday, 09'th Apr 2023
Generally speaking, biotech stocks to buy offer investors an excellent opportunity for significant upside success. According to Grand View Research, the global market size for the industry reached $1.
Why Amylyx Pharmaceuticals Stock Is Bolting Higher Today
12:31pm, Tuesday, 14'th Mar 2023
Amylyx Pharmaceuticals scored a major regulatory approval with its amyotrophic lateral sclerosis (ALS) drug last year. The drug's sales far surpassed expectations in its first quarter on the market in
Amylyx, A Top 5% Biotech Stock, Just Scored A Huge Win In ALS Treatment
09:30am, Tuesday, 14'th Mar 2023
Amylyx's new ALS treatment crushed Wall Street's fourth-quarter expectations, pushing AMLX stock above its 50-day line Tuesday. The post Amylyx, A Top 5% Biotech Stock, Just Scored A Huge Win In ALS T
Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2022 Earnings Call Transcript
07:58pm, Monday, 13'th Mar 2023
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee -
These Are the Top 10 Holdings of David Kim
10:55pm, Monday, 06'th Mar 2023
David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 20
Amylyx: Patient Advocacy, If Not Drug Merit, Will See It Through
07:21am, Sunday, 26'th Feb 2023
AMLX got relyvrio approved through an interesting set of events. There are questions surrounding high price, low benefit, trial design, and so on.
100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make Miracles
06:42pm, Friday, 30'th Dec 2022
Historic 2022 inflation lifted energy and value stocks while sinking growth plays. The post 100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make Miracles appeared first on Investor's
Amylyx: Future Looks Good After Surprise Approval, But Unpredictable, Too
07:10pm, Thursday, 08'th Dec 2022
Amylyx Pharmaceuticals, Inc. received a surprise approval for Relyvrio in ALS. The approval is great for the once-small company.
These Are the 10 Best-Performing IPOs in 2022 Through October
09:21pm, Wednesday, 16'th Nov 2022
The IPO market has been slow this year as investors' risk appetite for new issues hit a record low.
